Michel Doumith
Overview
Explore the profile of Michel Doumith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
4370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mushtaq S, Vickers A, Doumith M, Garello P, Woodford N, Livermore D
J Antimicrob Chemother
. 2024 Dec;
80(3):645-656.
PMID: 39665271
Background: Antibiotic resistance complicates treatment of urinary infections, particularly when these ascend above the bladder, with few oral options remaining. New oral β-lactamase inhibitor combinations present a potential answer, with...
2.
Fifer H, Doumith M, Rubinstein L, Mitchell L, Wallis M, Singh S, et al.
J Antimicrob Chemother
. 2024 Oct;
79(12):3332-3339.
PMID: 39417254
Objectives: Since June 2022, there has been a rise in the number of ceftriaxone-resistant Neisseria gonorrhoeae cases detected in England (n = 15), of which a third were XDR. We...
3.
Alzayer M, Alkhulaifi M, Alyami A, Aldosary M, Alageel A, Garaween G, et al.
Infect Drug Resist
. 2024 Sep;
17:3715-3722.
PMID: 39221186
Published data on the molecular mechanisms underlying antimicrobial resistance in Group B (GBS) isolates from Saudi Arabia are lacking. Here, we aimed to determine the genetic basis of resistance to...
4.
Alzayer M, Alkhulaifi M, Alyami A, Aldosary M, Alageel A, Garaween G, et al.
Front Cell Infect Microbiol
. 2024 May;
14:1377993.
PMID: 38711928
Introduction: Detailed assessment of the population structure of group B (GBS) among adults is still lacking in Saudi Arabia. Here we characterized a representative collection of isolates from colonized and...
5.
Alzayer M, Alkhulaifi M, Alyami A, Aldosary M, Alageel A, Garaween G, et al.
J Glob Antimicrob Resist
. 2024 Mar;
36:493.
PMID: 38521550
No abstract available.
6.
Alzayer M, Alkhulaifi M, Alyami A, Aldosary M, Alageel A, Garaween G, et al.
J Glob Antimicrob Resist
. 2023 Oct;
35:244-251.
PMID: 37844802
Objectives: Group B Streptococcus (GBS) has emerged as an important cause of severe infections in adults. However, limited data are available regarding the epidemiology of GBS in Saudi Arabia. Methods:...
7.
Kanafani Z, Sleiman A, Frem J, Doumat G, Gharamti A, El Hafi B, et al.
Front Microbiol
. 2023 Sep;
14:1209224.
PMID: 37744929
Background: Fluoroquinolones are some of the most used antimicrobial agents for the treatment of . This study aimed at exploring the differential activity of ciprofloxacin and levofloxacin on the selection...
8.
Alqurashi M, Alsaedy A, Alalwan B, Alzayer M, Alswaji A, Okdah L, et al.
Pathogens
. 2022 Dec;
11(12).
PMID: 36558809
is a rare and unique species among the genus that has not been previously reported as a cause of male genitourinary tract infection. In this report, we describe a case...
9.
Alzayer M, Alghoribi M, Alalwan B, Alreheli A, AlJohani S, Bosaeed M, et al.
J Glob Antimicrob Resist
. 2022 Dec;
32:176-180.
PMID: 36481491
Objectives: Cefiderocol is a novel catechol-substituted siderophore cephalosporin with broad-spectrum activity against Gram-negative pathogens. However, variation of its activity among carbapenemase producers from various regions and countries has been reported....
10.
Alsaedi A, Alharbi M, Ossenkopp J, Farahat F, Taguas R, Algarni M, et al.
J Infect Public Health
. 2022 Oct;
15(11):1279-1286.
PMID: 36274368
Background: Nosocomial outbreaks frequently occurred during the Coronavirus disease 2019 (COVID-19) pandemic; however, sharing experiences on outbreak containment is vital to reduce the related burden in different locations. Objectives: This...